StockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Stock analysts at StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Aeterna Zentaris stock opened at $6.32 on Thursday. The company has a market capitalization of $11.31 million, a P/E ratio of -0.43 and a beta of 1.55. Aeterna Zentaris has a fifty-two week low of $3.96 and a fifty-two week high of $12.80. The stock has a 50-day simple moving average of $6.97 and a 200-day simple moving average of $7.51.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) EPS for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.